Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trametinib - Novartis

Drug Profile

Trametinib - Novartis

Alternative Names: 1120212; CE-Trametinib; GSK-1120212; GSK-1120212B; JTP-74057; Mecinist; Mekinist; Mekinisuto; Meqsel; Spexotras; Tasu Mekinisuto; TMT-212; Trametinib dimethyl sulfoxide; Trametinib DMSO

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer BeiGene; Bristol-Myers Squibb; Dana-Farber Cancer Institute; GlaxoSmithKline; GSK; Japan Tobacco; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Novartis; Pfizer; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antidementias; Antineoplastics; Cyclopropanes; Fluorobenzenes; Iodobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Glioma; Thyroid cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Registered Acral lentiginous melanoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Brain metastases; Cancer; Cervical cancer; Endometrial cancer; Multiple myeloma; Myeloid leukaemia; Pancreatic cancer; Triple negative breast cancer; Uveal melanoma
  • Phase I/II Colorectal cancer
  • Phase I Adenocarcinoma
  • No development reported Leukaemia; Lymphoma; Malignant-mesothelioma
  • Discontinued Inflammation

Most Recent Events

  • 16 Jul 2024 Launched for Malignant melanoma (Combination therapy, First-line therapy, Metastatic disease) in Australia (PO) before July 2024
  • 16 Jul 2024 Launched for Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Monotherapy) in Australia (PO) before July 2024
  • 15 Jul 2024 Launched for Glioma (Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in USA (PO) before July 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top